HOUSE_OVERSIGHT_024711.jpg
2.35 MB
Extraction Summary
0
People
7
Organizations
2
Locations
4
Events
2
Relationships
3
Quotes
Document Information
Type:
Investment research report / legal analysis (page 75)
File Size:
2.35 MB
Summary
This document is page 75 of a 2017 report by Ackrell Capital, LLC, titled 'Chapter IV U.S. Legal Landscape.' It details FDA regulations regarding 'off-label' prescriptions and specifically analyzes 'Cannabinoid-Based Drugs' such as Marinol, Syndros, Cesamet, Sativex, and Epidiolex. It discusses their scheduling under the Controlled Substances Act (CSA) and the status of their FDA approvals as of October 2017. The document bears a 'HOUSE_OVERSIGHT_024711' stamp, indicating it was part of a document production for the House Oversight Committee.
Organizations (7)
Timeline (4 events)
Locations (2)
| Location | Context |
|---|---|
Relationships (2)
Sativex and Epidiolex (both manufactured by U.K.-based GW Pharmaceuticals)
Sativex and Epidiolex (both manufactured by U.K.-based GW Pharmaceuticals)
Key Quotes (3)
"A drug generally may not be marketed for treating a condition other than a condition for which the FDA has found the drug to be a safe and effective treatment"Source
HOUSE_OVERSIGHT_024711.jpg
Quote #1
"The FDA has not approved any drug derived from the cannabis plant."Source
HOUSE_OVERSIGHT_024711.jpg
Quote #2
"If approved by the FDA, Epidiolex would be the first FDA-approved pharmaceutical derived from cannabis."Source
HOUSE_OVERSIGHT_024711.jpg
Quote #3
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document